JP2016534153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534153A5 JP2016534153A5 JP2016547977A JP2016547977A JP2016534153A5 JP 2016534153 A5 JP2016534153 A5 JP 2016534153A5 JP 2016547977 A JP2016547977 A JP 2016547977A JP 2016547977 A JP2016547977 A JP 2016547977A JP 2016534153 A5 JP2016534153 A5 JP 2016534153A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- administration
- subject
- powder
- additive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 239000000654 additive Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 229960003136 leucine Drugs 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000004067 bulking agent Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000004469 amino acid formulation Substances 0.000 claims 1
- 230000009084 cardiovascular function Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889887P | 2013-10-11 | 2013-10-11 | |
| US61/889,887 | 2013-10-11 | ||
| PCT/US2014/060039 WO2015054574A1 (en) | 2013-10-11 | 2014-10-10 | Spray dry formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019024568A Division JP6823095B2 (ja) | 2013-10-11 | 2019-02-14 | 噴霧乾燥製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534153A JP2016534153A (ja) | 2016-11-04 |
| JP2016534153A5 true JP2016534153A5 (enExample) | 2017-11-16 |
| JP6483714B2 JP6483714B2 (ja) | 2019-03-13 |
Family
ID=52813663
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547977A Active JP6483714B2 (ja) | 2013-10-11 | 2014-10-10 | 噴霧乾燥製剤 |
| JP2019024568A Active JP6823095B2 (ja) | 2013-10-11 | 2019-02-14 | 噴霧乾燥製剤 |
| JP2021001507A Pending JP2021063119A (ja) | 2013-10-11 | 2021-01-07 | 噴霧乾燥製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019024568A Active JP6823095B2 (ja) | 2013-10-11 | 2019-02-14 | 噴霧乾燥製剤 |
| JP2021001507A Pending JP2021063119A (ja) | 2013-10-11 | 2021-01-07 | 噴霧乾燥製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9925184B2 (enExample) |
| EP (1) | EP3054937B1 (enExample) |
| JP (3) | JP6483714B2 (enExample) |
| CN (2) | CN111743901B (enExample) |
| AU (3) | AU2014331796B2 (enExample) |
| CA (1) | CA2926793C (enExample) |
| ES (1) | ES2959419T3 (enExample) |
| WO (1) | WO2015054574A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| CN109568319A (zh) | 2013-01-10 | 2019-04-05 | 普尔莫凯恩股份有限公司 | 非选择性激酶抑制剂 |
| CN105473133A (zh) | 2013-04-30 | 2016-04-06 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
| SI3060041T1 (sl) | 2013-10-25 | 2021-04-30 | Insmed Incorporated | Spojine prostaciklina |
| EP3904326A1 (en) | 2014-11-18 | 2021-11-03 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| AU2017211410B2 (en) * | 2016-01-29 | 2022-10-13 | Mannkind Corporation | Dry powder inhaler |
| US10898494B2 (en) * | 2016-05-05 | 2021-01-26 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| GB201609940D0 (en) * | 2016-06-07 | 2016-07-20 | Novabiotics Ltd | Microparticles |
| CA3027970A1 (en) * | 2016-06-17 | 2017-12-21 | United Therapeutics Corporation | Extracellular vesicles with enhanced potency |
| CN110087653A (zh) * | 2016-10-27 | 2019-08-02 | 普尔莫凯恩股份有限公司 | 用于治疗肺高血压的组合疗法 |
| EP3684338A4 (en) | 2017-09-22 | 2021-06-23 | Otitopic Inc. | DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| US20210038510A1 (en) * | 2018-02-08 | 2021-02-11 | Pulmokine, Inc. | Formulations of kinase inhibitors and prostanoids |
| WO2020071448A1 (ja) * | 2018-10-02 | 2020-04-09 | 学校法人名城大学 | 吸入粉末剤、その評価方法及びその用途 |
| CN114072136B (zh) | 2019-04-29 | 2024-11-29 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| WO2020232238A1 (en) | 2019-05-16 | 2020-11-19 | Aerovate Therapeutics, Inc. | Inhalable formulations for kinase inhibition |
| US11464776B2 (en) | 2019-05-16 | 2022-10-11 | Aerovate Therapeutics, Inc. | Inhalable imatinib formulations, manufacture, and uses thereof |
| EP4069069A4 (en) | 2020-01-11 | 2024-07-03 | Third Pole, Inc. | SYSTEMS AND METHODS FOR NITROGEN OXIDE PRODUCTION WITH HUMIDITY CONTROL |
| WO2021201258A1 (ja) * | 2020-04-01 | 2021-10-07 | 株式会社ＳｔａｔｅＡｒｔ | 核酸含有組成物、核酸含有組成物の製造方法及び核酸導入方法 |
| CA3199091A1 (en) * | 2020-11-23 | 2022-05-27 | Aerovate Therapeutics, Inc. | Imatinib formulations, manufacture, and uses thereof |
| CN117157282A (zh) * | 2021-05-07 | 2023-12-01 | Gb002股份有限公司 | N-{3-[(1s)-1-{[6-(3,4-二甲氧基苯基)吡嗪-2-基]氨基}乙基]苯基}-5-甲基吡啶-3-甲酰胺的结晶形式及相关产品和方法 |
| CA3260897A1 (en) | 2022-08-10 | 2024-02-15 | Gb002, Inc. | Polytherapy based on a tyrosine kinase inhibitor and a type 2 activin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH) |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118401A (en) | 1977-10-19 | 1978-10-03 | American Hoechst Corporation | Preparation of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid and precursors therefor |
| JPS5488231A (en) | 1977-12-22 | 1979-07-13 | Sumitomo Chem Co Ltd | 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| DE3632329A1 (de) | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| US5648369A (en) | 1991-11-20 | 1997-07-15 | University Of Kentucky Research Foundation | Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists |
| BR9610048A (pt) | 1995-08-30 | 1999-07-06 | Bayer Ag | Acil amino salicilamidas |
| JPH09268169A (ja) | 1996-04-01 | 1997-10-14 | Otsuka Chem Co Ltd | サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤 |
| DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| WO2001013891A2 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| US6451823B1 (en) | 1999-09-23 | 2002-09-17 | G.D. Searle & Co. | Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity |
| KR100681724B1 (ko) | 1999-10-19 | 2007-02-28 | 머크 앤드 캄파니 인코포레이티드 | 티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물 |
| JP2003512353A (ja) | 1999-10-19 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP2003523390A (ja) | 2000-02-25 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害薬 |
| EP1363702A4 (en) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| CA2486187C (en) | 2002-05-23 | 2013-02-19 | Cytopia Pty Ltd. | Kinase inhibitors |
| DE60323642D1 (de) | 2002-05-23 | 2008-10-30 | Cohen Ben Z | Medizinisch genaues pumpsystem |
| AUPS251502A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Protein kinase inhibitors |
| NZ537155A (en) | 2002-05-23 | 2006-09-29 | Cytopia Pty Ltd | Protein kinase inhibitors |
| WO2004002531A1 (ja) | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 血管の収縮または拡張による疾患治療剤 |
| AU2003246927A1 (en) | 2002-07-03 | 2004-01-23 | Astex Technology Limited | 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors |
| KR20050029209A (ko) | 2002-07-15 | 2005-03-24 | 미리어드 제네틱스, 인크. | 화합물, 조성물 및 이의 사용방법 |
| WO2004037261A1 (en) | 2002-10-25 | 2004-05-06 | The Administrators Of The Tulane Educational Fund | Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
| US20050026879A1 (en) | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| FR2858459B1 (fr) | 2003-08-01 | 2006-03-10 | Commissariat Energie Atomique | Commutateur micro-mecanique bistable, methode d'actionnement et procede de realisation correspondant |
| AU2004263148B2 (en) | 2003-08-06 | 2008-08-21 | Vertex Pharmaceuticals, Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| TWI347940B (en) | 2003-11-07 | 2011-09-01 | Novartis Ag | Methods for synthesizing quinolinone compounds |
| NZ545694A (en) | 2003-12-03 | 2010-04-30 | Ym Bioscience Australia Pty Lt | Azole-based kinase inhibitors |
| PT2277865E (pt) | 2003-12-03 | 2015-02-05 | Ym Biosciences Australia Pty | Heterociclos de azoto de anel de 6 membros fenil substituídos como inibidores de polimerização de microtúbulos |
| US20080207613A1 (en) | 2004-01-12 | 2008-08-28 | Cytopia Research Pty Ltd | Selective Kinase Inhibitors |
| WO2005114219A2 (en) | 2004-05-20 | 2005-12-01 | Wyeth | Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases |
| JP2006111553A (ja) | 2004-10-13 | 2006-04-27 | Dainippon Sumitomo Pharma Co Ltd | スルホニルオキシインドール誘導体及びそれを含有する医薬組成物 |
| PL1948176T3 (pl) | 2005-11-10 | 2011-05-31 | Bayer Schering Pharma Ag | Diarylomoczniki do leczenia nadciśnienia płucnego |
| WO2007087575A2 (en) | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| US8410173B2 (en) | 2006-02-28 | 2013-04-02 | Ym Biosciences Australia Pty Ltd | Inhibition of JAK2 as a treatment of pulmonary arterial hypertension |
| WO2007124382A2 (en) * | 2006-04-19 | 2007-11-01 | Novartis Vaccines And Diagnostics, Inc. | Inhaled imipenem |
| LT2848610T (lt) * | 2006-11-15 | 2017-11-10 | Ym Biosciences Australia Pty Ltd | Kinazės aktyvumo inhibitoriai |
| WO2008137605A1 (en) | 2007-05-04 | 2008-11-13 | Irm Llc | Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors |
| EP2152688A1 (en) | 2007-05-04 | 2010-02-17 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| WO2009026204A1 (en) | 2007-08-22 | 2009-02-26 | Irm Llc | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
| KR20120107538A (ko) | 2007-08-22 | 2012-10-02 | 아이알엠 엘엘씨 | 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물 |
| RS52270B (sr) | 2007-12-20 | 2012-10-31 | Bayer Pharma Aktiengesellschaft | 4-(4-cijano-2-tioaril)-dihidropirimidinon i njegova primena |
| NZ590839A (en) | 2008-08-13 | 2013-02-22 | Novartis Ag | Treatment of pulmonary arterial hypertension |
| DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
| WO2010102066A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Dextran polymer powder for inhalation administration of pharmaceuticals |
| WO2010132827A1 (en) | 2009-05-15 | 2010-11-18 | Bend Research, Inc. | Low-molecular dextran for powder inhalations |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
| EP2618924A1 (en) | 2010-09-24 | 2013-07-31 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| MX346244B (es) * | 2011-05-19 | 2017-03-13 | Savara Inc | Composiciones de vancomicina en polvo seco y metodos asociados. |
| WO2013033167A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| WO2014110198A2 (en) | 2013-01-10 | 2014-07-17 | Zisman Lawrence S | Therapeutic indications of kinase inhibitors |
| CN109568319A (zh) | 2013-01-10 | 2019-04-05 | 普尔莫凯恩股份有限公司 | 非选择性激酶抑制剂 |
| JP6799201B2 (ja) | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク． | エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 |
| WO2015179369A1 (en) | 2014-05-20 | 2015-11-26 | Infinity Pharmaceuticals, Inc. | Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors |
-
2014
- 2014-10-10 WO PCT/US2014/060039 patent/WO2015054574A1/en not_active Ceased
- 2014-10-10 JP JP2016547977A patent/JP6483714B2/ja active Active
- 2014-10-10 ES ES14852309T patent/ES2959419T3/es active Active
- 2014-10-10 CN CN202010266778.2A patent/CN111743901B/zh active Active
- 2014-10-10 CN CN201480067999.XA patent/CN106132403B/zh active Active
- 2014-10-10 AU AU2014331796A patent/AU2014331796B2/en active Active
- 2014-10-10 US US15/028,347 patent/US9925184B2/en active Active
- 2014-10-10 CA CA2926793A patent/CA2926793C/en active Active
- 2014-10-10 EP EP14852309.5A patent/EP3054937B1/en active Active
-
2017
- 2017-11-10 US US15/809,054 patent/US20180193336A1/en not_active Abandoned
-
2019
- 2019-02-14 JP JP2019024568A patent/JP6823095B2/ja active Active
-
2020
- 2020-04-16 AU AU2020202556A patent/AU2020202556A1/en not_active Abandoned
-
2021
- 2021-01-07 JP JP2021001507A patent/JP2021063119A/ja active Pending
-
2022
- 2022-05-27 AU AU2022203611A patent/AU2022203611A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534348A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| JP2015057436A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| JP2011502997A5 (enExample) | ||
| JP2012503668A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| MX2013013503A (es) | Composiciones de vancomicina en polvo seco y metodos asociados. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| JP2016534142A5 (enExample) | ||
| JP2019507781A5 (enExample) | ||
| JP2019528320A5 (enExample) | ||
| JP2015525763A5 (enExample) | ||
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| JP2016510326A5 (enExample) | ||
| CA3019769C (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| FI3710036T3 (fi) | Stabiileja askorbiinihappokoostumuksia ja menetelmiä niiden käyttämiseksi | |
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| JP2015510916A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| JP2017532316A5 (enExample) | ||
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением |